Trial intelligence / Profile preview

Phase II open-label single-arm study of lorlatinib in Chinese patients with ROS1-positive advanced or metastatic non-small cell lung cancer after crizotinib and platinum chemotherapy

CTR20220649Phase 2Active

Sponsor

Pfizer

Start

May 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1